Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752028 | 0.79 | CHRNA7 (0.33) | POLBALDH1A1CHRNA7 | |
| SCHEMBL11455857 | 0.75 | — | — | |
| SCHEMBL1803997 | 0.75 | ALDH1A1 (0.37) | POLBALDH1A1 | |
| SCHEMBL6552259 | 0.71 | LMNA (0.39) | ALDH1A1CHRNA7LMNAALOX12 | |
| SCHEMBL6353020 | 0.71 | SMN1; SMN2 (0.38) | POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL16336091 | 0.71 | TRIM24 (0.31) | — | |
| SCHEMBL23124090 | 0.70 | — | — | |
| SCHEMBL26101713 | 0.70 | TRIM24 (0.33) | ALDH1A1 | |
| SCHEMBL20987575 | 0.68 | NEK2 (0.32) | POLBALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL20987576 | 0.68 | NEK2 (0.32) | POLBALDH1A1CHRNA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118056834-A | Fused ring pyridone derivatives, preparation method and application thereof | 合肥医工医药股份有限公司 | 2024-05-21 | — | — | CN | disclosed |
| EP-3652180-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | Dart NeuroScience LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| US-7943605-B2 | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses | UCB PHARMA S.A. (BE) | 2011-05-17 | — | — | US | disclosed |
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-22 | — | — | US | disclosed |
| EP-0854857-A1 | METHOD OF PREPARING OPTICALLY ACTIVE $g(a)-AMINO ACIDS AND $g(a)-AMINO ACID DERIVATIVES | DEGUSSA AG (DE) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997010203-A1 | METHOD OF PREPARING OPTICALLY ACTIVE α-AMINO ACIDS AND α-AMINO ACID DERIVATIVES | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023708-A1 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses | COASY, FURIN, PEPD | POLB 1897/4885ALDH1A1 1149/4885CHRNA7 4688/4885 |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | POLB 4050/4885ALDH1A1 359/4885CHRNA7 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.